Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-controlled infusion of remimazolam with common anesthetic drugs
ChiCTR2400084302Phase 4Not yet recruiting
- Sponsor
- Affiliated Cancer Hospital of Xinjiang Medical University
- Start
- May 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of remimazolam, propofol, sufentanil, remifentanil, esketamine and 1 more (5 arms), sponsored by Affiliated Cancer Hospital of Xinjiang Medical University. Primary endpoints: Bispectral index and Blood pressure. Planned start May 2024; status: not yet recruiting.
02
Drugs
remimazolampropofolsufentanilremifentanilesketamine
Beyond the preview
Go deeper on ChiCTR2400084302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400084302.